Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 1 of 15. Medicare Part B Medical Policy

Transcription

1 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 1 of 15 Medicare Part B Medical Policy Positron Emission Tomography (PET) Scans (AC ) "CPT codes, descriptions, and other data only are copyright 1999 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Apply." Description: Positron emission tomography (PET), also known at positron emission transverse tomography (PETT), or positron emission coincident imaging (PECI), is a non-invasive imaging procedure that assesses perfusion and the level of metabolic activity in various organ systems of the human body. A positron camera (tomograph) is used to produce cross-sectional tomographic images by detecting radioactivity from a radioactive tracer substance (radiopharmaceutical) that is injected into the patient. Medicare has been continuously reviewing scientific literature regarding PET scans and has established coverage as indicated in the Indications and Limitations of Coverage section of this document. As with other new or evolving technologies, HCFA will continue to review the progress of this technology, with a view toward modifying policy, based on the best evidence available as to the medical effectiveness of such scans. All other uses of PET scans not addressed here remain not covered by Medicare. Most PET scans utilizing the glucose analog 2[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) involve the IV administration of FDG with image acquisition usually beginning minutes later, and continuing for minutes. The FDG is metabolized by both normal and cancerous tissue in proportion to the rate of glycolysis. Since tumor cells have shown an increased utilization of glucose, those regions observed to have an increased FDG uptake relative to background indicate areas of cancerous tissue. For all uses of PET, excluding Rubidium 82 for perfusion of the heart, myocardial viability and refractory seizures the following definitions apply: 1. Diagnosis: PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal and colorectal cancers, as well as in melanoma, should be rare. PET is not covered for other diagnostic uses, and is not covered for screening (testing of patients without specific signs and symptoms of disease). 2. Staging and/or Restaging: PET is covered in clinical situations in which (1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or, (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient and, (2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. 3. Monitoring: Use of PET to monitor tumor response during the planned course of therapy (i.e. when no change in therapy is being contemplated) is NOT covered. Restaging only occurs after a course of treatment is completed, and this is covered, subject to the conditions above. For staging and restaging: PET is covered in either/or both of the following circumstances: 1. The stage of the cancer remains in doubt after completion of a standard diagnostic workup, including

2 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 2 of 15 conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound). 2. The clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. PET is not covered for other diagnostic uses, and is not covered for screening (testing of patients without specific symptoms). Use of PET to monitor tumor response during the planned course of therapy (i.e. when no change in therapy is being contemplated) is not covered. Policy Type: Local Medical Review Policy HCPCS Section, Benefit Category: Radiology CPT/ HCPCS Codes: G0030 G0031 G0032 G0033 G0034 G0035 PET myocardial perfusion imaging, (following previous PET, G0030-G0047); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following previous PET, G0030-G0047); multiple studies, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest SPECT, 78464); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest SPECT, 78464); multiple studies, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest SPECT, 78465); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest SPECT, 78465); multiple studies, rest or stress (exercise and/or pharmacologic) G0036 PET myocardial perfusion imaging, (following coronary angiography, ); single study, rest or stress (exercise and/or pharmacologic) G0037 PET myocardial perfusion imaging, (following coronary angiography, ); multiple studies, rest or stress (exercise and/or pharmacologic) G0038 G0039 G0040 G0041 G0042 G0043 G0044 G0045 PET myocardial perfusion imaging, (following stress planar myocardial perfusion, 78460); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress planar myocardial perfusion, 78460); multiple studies, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress echocardiogram, 93350); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress echocardiogram, 93350); multiple studies, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress nuclear ventriculogram, or 78483); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress nuclear ventriculogram, or 78483); multiple studies, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest ECG, 93000); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following rest ECG, 93000); multiple studies, rest or stress (exercise and/or pharmacologic)

3 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 3 of 15 G0046 G0047 G0125 G0210 PET myocardial perfusion imaging, (following stress ECG, 93015); single study, rest or stress (exercise and/or pharmacologic) PET myocardial perfusion imaging, (following stress ECG, 93015); multiple studies, rest or stress (exercise and/or pharmacologic) PET imaging regional or whole body; single pulmonary nodule Short Description: PET image pulmonary nodule PET Imaging whole body; diagnosis; lung cancer, non-small cell Short Description: PET img wholebody dxlung ca G0211 PET Imaging whole body; initial staging; lung cancer; non-small cell (replaces G0126) G0212 G0213 G0214 Short Description: PET img wholbody init lung PET Imaging whole body; restaging; lung cancer; non-small cell Short Description: PET img wholebod restag lung PET Imaging, whole body; diagnosis; colorectal cancer Short Description: PET img wholbody dx colorec PET Imaging whole body; initial staging; colorectal cancer Short Description: PET img wholebod init colore G0215 PET Imaging whole body; restaging; colorectal cancer (replaces G0163) G0216 G0217 Short Description: PET img wholebod restag colore PET Imaging whole body; diagnosis; melanoma Short Description: PET img wholebod dx melanoma PET Imaging whole body; initial staging; melanoma Short Description: PET img wholebod init melano G0218 PET Imaging whole body; restaging; melanoma (replaces G0165) G0219 G0220 Short Description: PET img wholebod restag mela PET Imaging whole body; melanoma for non-covered indications Short Description: PET img wholbod melano nonco PET Imaging whole body; diagnosis; lymphoma Short Description: PET img wholebod dx lymphoma G0221 PET Imaging whole body; initial staging; lymphoma (replaces G0164) Short Description: PET imag wholbod init lympho G0222 PET Imaging whole body; restaging; lymphoma (replaces G0164) G0223 Short Description: PET imag wholbod resta lymph PET Imaging whole body or regional; diagnosis; head and neck cancer; excluding thyroid and CNS cancers Short Description: PET imag wholbod reg dx head

4 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 4 of 15 G0224 G0225 G0226 G0227 G0228 G0229 G0230 PET Imaging whole body or regional; initial staging; head and neck cancer; excluding thyroid and CNS cancers Short Description: PET imag wholbod reg ini hea PET Imaging whole body or regional; staging; head and neck cancer, excluding thyroid and CNS cancers Short Description: PET whol restag headneckonly PET Imaging whole body; diagnosis; esophageal cancer Short Description: PET img wholbody dx esophagl PET Imaging whole body; initial staging; esophageal cancer Short Description: PET img wholbod ini esophage PET Imaging whole body; restaging; esophageal cancer Short Description: PET img wholbod restg esopha PET Imaging; Metabolic brain imaging for pre-surgical evaluation of refractory seizures Short Description: PET img metaboloc grain pres PET Imaging; Metabolic assessment for myocardial viability following inconclusive SPECT study Short Description: PET myocard viability posts NOTE: G0125 has a definition change: "PET imaging regional or whole body; single pulmonary nodule" HCFA's National Coverage Policy: Title XVIII of the Social Security Act, section 1862(a)(7) excludes routine physical examination and screening tests performed in the absence of signs or symptoms from coverage. Title XVIII of the Social Security Act, section 1862(a)(1)(A) allows coverage and payment for services considered medically reasonable and necessary. Title XVIII of the Social Security Act, section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim. Coverage Issues ICD-9-CM Codes: Malignant neoplasm of lip Malignant neoplasm of tongue Malignant neoplasm of major salivary glands Malignant neoplasm of gum Malignant neoplasm of floor of mouth Malignant neoplasm of other and unspecified parts of mouth Malignant neoplasm of oropharynx Malignant neoplasm of nasopharynx

5 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 5 of Malignant neoplasm of hypopharynx Malignant neoplasm of other and ill-defined sites with the lip, oral cavity, and pharynx Malignant neoplasm of esophagus Malignant neoplasm of colon Malignant neoplasm of rectum, rectosigmoid junction, and anus; rectosigmoid junction Malignant neoplasm of trachea, bronchus and lung Malignant melanoma of skin Malignant neoplasm of head, face, and neck Lymphosarcoma and reticulosarcoma; reticulosarcoma Lymphosarcoma and reticulosarcoma; lymphosarcoma Burkitt s tumor or lymphoma Hodgkin s paragranuloma Hodgkin s granuloma Hodgkin s sarcoma Hodgkin s disease; lympocytic-histocytic predominance Hodgkin s disease; nodular sclerosis Hodgkin s disease; mixed cellularity Hodgkin s disease; lymphocytic deletion Hodgkin s disease; unspecified Nodular lymphoma Mycosis fungoides Sezary s disease Malignant histiocytosis Leukemic reticuloendotheliosis Letterer-Siwe disease Malignant mast cell tumors Other lymphomas Other and unspecified malignant neoplasms of lymphoid and histocytic tissue Generalized nonconvulsive epilepsy, intractable Generalized convulsive epilepsy, intractable Acute myocardial infarction Other acute and subacute forms of ischemic heart disease Angina pectoris Coronary atherosclerosis Aneurysm of heart Other specified forms of chronic ischemic heart disease Chronic ischemic heart disease, unspecified Lung field, coin lesion Indications and Limitations of Coverage and/or Medical Necessity: NOTE: This section is a verbatim excerpt from the Medicare Coverage Issues Manual (CIM), Section All uses of PET scans not listed in the CIM are NOT covered.

6 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 6 of 15 Clinical Condition Effective Date Coverage Solitary Pulmonary Nodules (SPNs) January 1, 1998 Characterization Lung Cancer (Non Small Cell) January 1, 1998 Initial staging Lung Cancer (Non Small Cell) July 1, 2001 Diagnosis, staging and restaging Esophageal Cancer July 1, 2001 Diagnosis, staging and restaging Colorectal Cancer July 1, 1999 Determining location of tumors if rising CEA level suggests recurrence Colorectal Cancer July 1, 2001 Diagnosis, staging and restaging Lymphoma July 1, 1999 Staging and restaging only when used as an alternative to Gallium scan Lymphoma July 1, 2001 Diagnosis, staging and restaging Melanoma July 1, 1999 Evaluating recurrence prior to surgery as an alternative to a Gallium scan Melanoma July 1, 2001 Diagnosis, staging and restaging; Non-covered for evaluating regional nodes Head and Neck Cancers (excluding CNS and thyroid) July 1, 2001 Diagnosis, staging and restaging Myocardial Viability July 1, 2001 Covered only following inconclusive SPECT Refractory Seizures July 1, 2001 Covered for pre-surgical evaluation only Perfusion of the heart using Rubidium 82* tracer March 14, 1995 Covered for noninvasive imaging of the perfusion of the heart [ I.A] A. Regardless of any other terms or conditions, all uses of FDG PET scans, in order to be covered by the Medicare program, must meet the following general conditions prior to June 30, 2001: [ I.A.1] 1. Such scans must be performed using a camera that has either been approved or cleared for marketing by the FDA to image radionuclides in the body. [ I.A.2] 2. Submission of claims for payment must include any information Medicare requires to assure that the PET scans performed were: (a) medically necessary; (b) did not unnecessarily duplicate other covered diagnostic tests, and (c) did not involve investigational drugs or procedures using investigational drugs, as determined by the Food and Drug Administration (FDA). [ I.A.3] 3. The PET scan entity submitting claims for payment must keep such patient records as Medicare requires on file for each patient for whom a PET scan claim is made. [ I.B] B. Regardless of any other terms or conditions, all uses of FDG PET scans, in order to be covered by the Medicare program, must meet the following general conditions as of July 1, 2001: [ I.B.1] 1. PET scans are covered for those indications otherwise listed in this document. For indications covered beginning July 1, 2001, scans performed with dedicated full-ring scanners will be covered. In the decision memorandum of December 15, 2000, HCFA had indicated that gamma camera systems with at least a 1-inch thick crystal would be eligible for coverage. However, coverage of PET using camera-based systems is now under further review as a separate national coverage determination. A final decision on what systems other than dedicated PET will be eligible for coverage, if any, will be announced prior to July 1, For those indications covered prior to July 1, 2001, all PET scanners approved or cleared for marketing by the FDA remain covered. [ I.B.2] 2. The provider of the PET scan should maintain on file the doctor's referral and documentation that the procedure involved only FDA approved drugs and devices, as is normal business practice.

7 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 7 of 15 [ I.B.3] 3. The ordering physician is responsible for documenting the medical necessity of the study and that it meets the conditions specified in the instructions. The physician should have documentation in the beneficiary's medical record to support the referral to the PET scan provider. [ I.B.4] 4. Medicare coverage is predicated upon the use of PET scans with FDG for the purpose of development of appropriate treatment plans for patients. HCFA will evaluate both the data produced by claims for these services, and data obtained from other sources, to determine whether, and to what extent, this coverage policy may need additional modification in order to assure that the services covered are medically effective for the treatment of Medicare beneficiaries. [ III] III. Covered Indications for PET Scans and Limitations/Requirements for Usage For all uses of PET relating to malignancies the following conditions apply: [ III.1] 1. Diagnosis: PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. PET is not covered for other diagnostic uses, and is not covered for screening (testing of patients without specific signs and symptoms of disease). [ III.2] 2. Staging and or Restaging: PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. [ III.3] 3. Monitoring: Use of PET to monitor tumor response during the planned course of therapy (i.e. when no change in therapy is being contemplated) is not covered. Restaging only occurs after a course of treatment is completed, and this is covered, subject to the conditions above. NOTE: In the absence of national frequency limitations, contractors may, if necessary, develop frequency requirements on any or all of the indications covered on and after July 1, [ IV] IV. Coverage of PET for Perfusion of the Heart Using Rubidium 82 Effective for services performed on or after March 14, 1995, PET scans performed at rest or with pharmacological stress used for noninvasive imaging of the perfusion of the heart for the diagnosis and management of patients with known or suspected coronary artery disease using the FDA-approved radiopharmaceutical Rubidium 82 (Rb 82) are covered, provided the requirements below are met. Requirements:

8 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 8 of 15 The PET scan, whether at rest alone, or rest with stress, is performed in place of, but not in addition to, a single photon emission computed tomography (SPECT); or The PET scan, whether at rest alone or rest with stress, is used following a SPECT that was found to be inconclusive. In these cases, the PET scan must have been considered necessary in order to determine what medical or surgical intervention is required to treat the patient. (For purposes of this requirement, an inconclusive test is a test(s) whose results are equivocal, technically uninterpretable, or discordant with a patient's other clinical data and must be documented in the beneficiary's file.) For any PET scan for which Medicare payment is claimed for dates of services prior to July 1, 2001, the claimant must submit additional specified information on the claim form (including proper codes and/or modifiers), to indicate the results of the PET scan. The claimant must also include information on whether the PET scan was done after an inconclusive noninvasive cardiac test. The information submitted with respect to the previous noninvasive cardiac test must specify the type of test done prior to the PET scan and whether it was inconclusive or unsatisfactory. These explanations are in the form of special G codes used for billing PET scans using Rb 82. Beginning July 1, 2001 claims should be submitted with the appropriate codes. [ V] V. Coverage of FDG PET for Lung Cancer The coverage for FDG PET for lung cancer, effective January 1, 1998, has been expanded. Beginning July 1, 2001 usage of FDG PET for lung cancer has been expanded to include diagnosis, staging, and restaging (see section III) of the disease. [ V.A] A. Effective for services performed on or after January 1, 1998, Medicare covers regional FDG PET chest scans, on any FDA approved scanner, for the characterization of single pulmonary nodules (SPNs). The primary purpose of such characterization should be to determine the likelihood of malignancy in order to plan future management and treatment for the patient. Beginning July 1, 2001, documentation should be maintained in the beneficiary's medical file at the referring physician's office to support the medical necessity of the procedure, as is normal business practice. Requirements: There must be evidence of primary tumor. Claims for regional PET chest scans for characterizing SPNs should include evidence of the initial detection of a primary lung tumor, usually by computed tomography (CT). This should include, but is not restricted to, a report on the results of such CT or other detection method, indicating an indeterminate or possibly malignant lesion, not exceeding four centimeters (cm) in diameter. PET scan claims must include the results of concurrent thoracic CT (as noted above), which is necessary for anatomic information, in order to ensure that the PET scan is properly coordinated with other diagnostic modalities. In cases of serial evaluation of SPNs using both CT and regional PET chest scanning, such PET scans will not be covered if repeated within 90 days following a negative PET scan. NOTE: A tissue sampling procedure (TSP) is not routinely covered in the case of a negative PET scan for characterization of SPNs, since the patient is presumed not to have a malignant lesion, based upon the PET scan results. When there has been a negative PET, the provider must submit additional information with the claim to support the necessity of a TSP, for review by the Medicare contractor. [ V.B] B. Effective for services performed from January 1, 1998 through June 30, 2001, Medicare approved coverage of FDG PET for initial staging of non-small-cell lung carcinoma (NSCLC). Limitations: This service is covered only when the primary cancerous lung tumor has been pathologically confirmed; claims for PET must include a statement or other evidence of the detection of such primary lung tumor. The evidence should include, but is not restricted to, a surgical pathology report, which documents the presence of an NSCLC. Whole body PET scan results and results of concurrent computed tomography (CT)

9 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 9 of 15 and follow-up lymph node biopsy must be properly coordinated with other diagnostic modalities. Claims must include both: The results of concurrent thoracic CT, necessary for anatomic information, and The results of any lymph node biopsy performed to finalize whether the patient will be a surgical candidate. The ordering physician is responsible for providing this biopsy result to the PET facility. NOTE: Where the patient is considered a surgical candidate, (given the presumed absence of metastatic NSCLC unless medical review supports a determination of medical necessity of a biopsy) a lymph node biopsy will not be covered in the case of a negative CT and negative PET. A lymph node biopsy will be covered in all other cases, i.e., positive CT + positive PET; negative CT + positive PET; positive CT + negative PET. [ V.C] C. Beginning July 1, 2001, Medicare covers FDG PET for diagnosis, staging, and restaging of NSCLC. Documentation should be maintained in the beneficiary's medical file to support the medical necessity of the procedure, as is normal business practice. Requirements: PET is covered in either/or both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation should be maintained in the beneficiary's medical record at the referring physician's office to support the medical necessity of the procedure, as is normal business practice. [ VI] VI. Coverage of FDG PET for Esophageal Cancer [ VI.A] A. Beginning July 1, 2001, Medicare covers FDG PET for the diagnosis, staging, and restaging of esophageal cancer. Medical evidence is present to support the use of FDG PET in pre-surgical staging of esophageal cancer. Requirements: PET is covered in either/or both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also

10 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 10 of 15 be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient, and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation should be maintained in the beneficiary's medical record at the referring physician's office to support the medical necessity of the procedure, as is normal business practice. [ VII] VII. Coverage of FDG PET for Colorectal Cancer Medicare coverage of FDG PET for colorectal cancer where there is a rising level of carcinoembryonic antigen (CEA) was effective July 1, 1999 through June 30, Beginning July 1, 2001 usage of FDG PET for colorectal cancer has been expanded to include diagnosis, staging, and restaging of the disease(see part III). [ VII.A] A. Effective July 1, 1999, Medicare covers FDG PET for patients with recurrent colorectal carcinomas, which are suggested by rising levels of the biochemical tumor marker CEA. [ VII.A.1] 1. Frequency Limitations: Whole body PET scans for assessment of recurrence of colorectal cancer cannot be ordered more frequently than once every 12 months unless medical necessity documentation supports a separate re-elevation of CEA within this period. [ VII.A.2] 2. Limitations: Because this service is covered only in those cases in which there has been a recurrence of colorectal tumor, claims for PET should include a statement or other evidence of previous colorectal tumor, through June 30, [ VII.B] B. Beginning July 1, 2001, Medicare coverage has been expanded for colorectal carcinomas for diagnosis, staging and re-staging. New medical evidence supports the use of FDG PET as a useful tool in determining the presence of hepatic/extrahepatic metastases in the primary staging of colorectal carcinoma, prior to selecting a treatment regimen. Use of FDG PET is also supported in evaluating recurrent colorectal cancer beyond the limited presentation of a rising CEA level where the patient presents clinical signs or symptoms of recurrence. Requirements: PET is covered in either/both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient, and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation that these conditions are met should be maintained by the referring physician in the

11 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 11 of 15 beneficiary's medical record, as is normal business practice. [ VIII] VIII. Coverage of FDG PET for Lymphoma Medicare coverage of FDG PET to stage and re-stage lymphoma as alternative to a Gallium scan, was effective July 1, Beginning July 1, 2001 usage of FDG PET for lymphoma has been expanded to include diagnosis, staging and restaging (see section III) of the disease. [ VIII.A] A. Effective July 1, 1999, FDG PET is covered for the staging and restaging of lymphoma. Requirements: FDG PET is covered only for staging or follow-up restaging of lymphoma. Claims must include a statement or other evidence of previous diagnosis of lymphoma when used as an alternative to a Gallium scan. To ensure that the PET scan is properly coordinated with other diagnostic modalities, claims must include the results of concurrent computed tomography (CT) and/or other diagnostic modalities when they are necessary for additional anatomic information. In order to ensure that the PET scan is covered only as an alternative to a Gallium scan, no PET scan may be covered in cases where it is done within 50 days of a Gallium scan done by the same facility where the patient has remained during the 50-day period. Gallium scans done by another facility less than 50 days prior to the PET scan will not be counted against this screen. The purpose of this screen is to assure that PET scans are covered only when done as an alternative to a Gallium scan within the same facility. We are aware that, in order to assure proper patient care, the treating physician may conclude that previously performed Gallium scans are either inconclusive or not sufficiently reliable. Frequency Limitation for Restaging: PET scans will be allowed for restaging no sooner than 50 days following the last staging PET scan or Gallium scan, unless sufficient evidence is presented to convince the Medicare contractor that the restaging at an earlier date is medically necessary. Since PET scans for restaging are generally done following cycles of chemotherapy, and since such cycles usually take at least 8 weeks, we believe this screen will adequately prevent medically unnecessary scans while allowing some adjustments for unusual cases. In all cases, the determination of the medical necessity for a PET scan for re-staging lymphoma is the responsibility of the local Medicare contractor. Beginning July 1, 2001, documentation should be maintained in the beneficiary's medical record at the referring physician's office to support the medical necessity of the procedure, as is normal business practice. [ VIII.B] B. Effective for services performed on or after July 1, 2001, the Medicare program has broadened coverage of FDG PET for the diagnosis, staging and restaging of lymphoma. Requirements: PET is covered in either/both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient, and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of

12 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 12 of 15 a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation that these conditions are met should be maintained by the referring physician in the beneficiary's medical record, as is normal business practice. [ IX] IX. Coverage of FDG PET for Melanoma Medicare covered the evaluation of recurrent melanoma prior to surgery when used as an alternative to a Gallium scan, effective July 1, For services furnished on or after July 1, 2001 FDG PET is covered for the diagnosis, staging, and restaging of malignant melanoma (see part III). FDG PET is not covered for the use of evaluating regional nodes in melanoma patients. [ IX.A] A. Effective for services furnished July 1, 1999 through June 30, 2001, in the case of patients with recurrent melanoma prior to surgery, FDG PET (when used as an alternative to a Gallium scan) is covered for tumor evaluation. Frequency Limitations: Whole body PET scans cannot be ordered more frequently than once every 12 months, unless medical necessity documentation, maintained in the beneficiaries medical record, supports the specific need for anatomic localization of possible recurrent tumor within this period. Limitations: The FDG PET scan is covered only as an alternative to a Gallium scan. PET scans can not be covered in cases where it is done within 50 days of a Gallium scan done by the same PET facility where the patient has remained under the care of the same facility during the 50-day period. Gallium scans done by another facility less than 50 days prior to the PET scan will not be counted against this screen. The purpose of this screen is to assure that PET scans are covered only when done as an alternative to a Gallium scan within the same facility. We are aware that, in order to assure proper patient care, the treating physician may conclude that previously performed Gallium scans are either inconclusive or not sufficiently reliable to make the determination covered by this provision. Therefore, we will apply this 50-day rule only to PET scans done by the same facility that performed the Gallium scan. Beginning July 1, 2001, documentation should be maintained in the beneficiary's medical file at the referring physician's office to support the medical necessity of the procedure, as is normal business practice. [ IX.B] B. Effective for services performed on or after July 1, 2001 FDG PET scan coverage for the diagnosis, staging and restaging of melanoma (not the evaluation regional nodes) has been broadened. Limitations: PET scans are not covered for the evaluation of regional nodes. Requirements: PET is covered in either/both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient, and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could

13 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 13 of 15 potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation that these conditions are met should be maintained by the referring physician in the beneficiary's medical file, as is normal business practice. [ X] X. Coverage of FDG PET for Head and Neck Cancers (Cancers of the Central Nervous System (CNS) and thyroid are non-covered) Effective for services performed on or after July 1, 2001, Medicare will provide coverage for cancer of the head and neck, excluding the central nervous system (CNS) and thyroid. The head and neck cancers encompass a diverse set of malignancies of which the majority is squamous cell carcinomas. Patients may present with metastases to cervical lymph nodes but conventional forms of diagnostic imaging fail to identify the primary tumor. Patients that present with cancer of the head and neck are left with two options either to have a neck dissection or to have radiation of both sides of the neck with random biopsies. PET scanning attempts to reveal the site of primary tumor to prevent the adverse effects of random biopsies or unneeded radiation. Limitations: PET scans for head and neck cancers are not covered for CNS or thyroid cancers. Requirements: PET is covered in either/or both of the following circumstances: Diagnosis - PET is covered only in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis. Therefore, the use of PET in the diagnosis of lymphoma, esophageal, and colorectal cancers as well as in melanoma should be rare. Staging and/or Restaging - PET is covered in clinical situations in which 1) (a) the stage of the cancer remains in doubt after completion of a standard diagnostic workup, including conventional imaging (computed tomography, magnetic resonance imaging, or ultrasound) or (b) the use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient, and 2) clinical management of the patient would differ depending on the stage of the cancer identified. PET will be covered for restaging after the completion of treatment for the purpose of detecting residual disease, for detecting suspected recurrence, or to determine the extent of a known recurrence. Use of PET would also be considered reasonable and necessary if it could potentially replace one or more conventional imaging studies when it is expected that conventional study information is insufficient for the clinical management of the patient. Documentation that these conditions are met should be maintained by the referring physician in the beneficiary's medical record, as is normal business practice. [ XI] XI. Coverage of FDG PET for Myocardial Viability Beginning July 1, 2001, Medicare covers FDG PET for the determination of myocardial viability, following an inconclusive SPECT. The identification of patients with partial loss of heart muscle movement or hibernating myocardium is important in selecting candidates with compromised ventricular function to determine appropriateness for revascularization. Diagnostic tests must distinguish between dysfunctional, but viable myocardial tissue and scar tissue, in order to affect management decisions. Limitations: In the event that a patient has received a single photon computed tomography test (SPECT) with inconclusive results, a PET scan may be covered. Documentation that these conditions are met should be maintained by the referring physician in the beneficiary's medical record, as is normal business practice. [ XII] XII. Coverage of FDG-PET for Refractory Seizures

14 Missouri Medicare Services -...: Positron Emission Tomography (PET) Scans (AC Page 14 of 15 Beginning July 1, 2001, Medicare will cover FDG-PET for pre-surgical evaluation for the purpose of localization of a focus of refractory seizure activity. Limitations: Covered only for pre-surgical evaluation. Documentation that these conditions are met should be maintained by the referring physician in the beneficiary's medical record, as is normal business practice. Reasons for Denial: Medicare will not cover this procedure if the patient does not meet all of the criteria listed in the Indications and Limitations of Coverage section of this policy. Non-Covered ICD-9-CM Codes: All diagnoses not listed as covered in the ICD-9-CM section of this policy. Sources of Information: Coverage Issues Coding Guidelines: 1. Consult current correct coding guidelines for applicable specific code combinations or reductions in payment due to specific codes billed. 2. HCPCS codes represent the global service so providers performing just the technical or professional component of the test should use modifier TC or 26, respectively and appropriately. 3. Instructions pertinent to each test are included in the section for that test. 4. The payment for the radiotracer, or radiopharmaceutical is included in the relative value units of the technical components of the above procedure codes. Separate payments for these agents for PET scans will not be allowed. 5. For services performed on or before June 30, 2001, providers must indicate the results of the PET scan and the previous test using a two digit modifier. (The modifier is not required for technical componentonly billings or billings to the intermediary.) The first character should indicate the result of the PET scan; the second character should indicate the results of the prior test. Depending on the procedure codes with which the modifiers are used, the meaning of the modifier will be apparent. The test result modifiers and their descriptions are as follows: (I) N, Negative; (II) E, Equivocal; (III) P, Positive, but not suggestive of, extensive ischemia or not suggestive of malignant single pulmonary nodule; and (IV) S, Positive and suggestive of; extensive ischemia (greater than 20 percent of the left ventricle) or malignant single pulmonary nodule. These modifiers may be used in any combination. For services performed on or after July 1, 2001, the requirement for these modifiers has been eliminated and these modifiers should not be used. Documentation Requirements: These requirements are listed at the beginning of this policy and within each section for the specific scans. Other Comments: Copyright, Current CPT (Physicians' Current Procedural Terminology), American Medical Association, All Rights Reserved. CAC Notes: This policy does not reflect the sole opinion of the carrier or carrier medical director. Although the final decision rests with the carrier, this policy was developed in cooperation with the Carrier Advisory Committee, which includes representatives from all recognized specialties within the state, and from HCFA/Medicare directives. The Arkansas consortium combined policy was presented in April 1999 in Arkansas and Missouri and accepted. This policy was also presented in August for Louisiana, Oklahoma and New Mexico as informational